Laura L. Gibson

Dr. Laura L. Gibson

Medicine, University of Massachusetts Medical School, Worcester, MA 01655, USA

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 February 2015 in Journal of Clinical Immunology
Verified
Journal Article
Closed access
PDF file
LGLaura L. Gibson
Laura L. Gibson
CBConstance M. Barysauskas
Constance M. Barysauskas
MMMargaret McManus
Margaret McManus
SDSheryl Dooley
Sheryl Dooley
DLDaniele Lilleri
Daniele Lilleri
KLKatherine Luzuriaga
Katherine Luzuriaga

15 June 2007 in The Journal of Infectious Diseases
Verified
Journal Article
Open access
PDF file
LGLaura L. Gibson
Laura L. Gibson
SDSheryl Dooley
Sheryl Dooley
STSonia Trzmielina
Sonia Trzmielina
MSMohan Somasundaran
Mohan Somasundaran
DFDonna Fisher
Donna Fisher
KLKatherine Luzuriaga
Katherine Luzuriaga
Cytomegalovirus (CMV) infection remains a significant cause of morbidity and mortality in young children. We have previously shown that CD8+ T cell r

4 October 2013 in Human Vaccines & Immunotherapeutics
Verified
Journal Article
Open access
PDF file
AGAnna Gil
Anna Gil
SSSiyuan Shen
Siyuan Shen
SCScott Coley
Scott Coley
LGLaura L. Gibson
Laura L. Gibson
DDDon Diamond
Don Diamond
SLShan Lu
Shan Lu
As a leading cause of congenital infection and a major threat to immunocompromised individuals, human cytomegalovirus (HCMV) is a major global public health concern. Effective HCMV vaccines would need to induce potent and balanced humoral and cellular immune responses. In this pilot study, immunogenicity studies were conducted in mice to examine HCMV antigen-specific antibody and T cell responses when a heterologous prime-boost immunization strategy was tested. DNA vaccines expressing either targets of protective antibody responses (gB and gM/gN) or well characterized T cell immunogens (pp65, pp150, and IE1) were used as the priming immunization while the live attenuated HCMV vaccine Towne strain was used as the boost, which may act like an inactivated vaccine due to the inability of HCMV to replicate in a mouse host. Our data indicate that while DNA vaccines were effective in priming HCMV-specific antibody responses, the final titers of gB- or gM-specific antibodies were not much different from those elicited by using multiple immunizations of HCMV alone. In contrast, DNA priming significantly enhanced T cell responses against gB, pp65, and IE1 as measured by IFN-γ. However, HCMV alone was not effective in eliciting strong T cell immune responses when used in a mouse host. Our data indicate that the complexity of antigen composition from a large virus, such as HCMV, may affect the profile of immune responses when viral vaccines are used as a boost.

28 April 2021 in IEEE Open Journal of Engineering in Medicine and Biology
Verified
Journal Article
Open access
LGLaura L. Gibson
Laura L. Gibson
NFNisha M. Fahey
Nisha M. Fahey
NHNathaniel Hafer
Nathaniel Hafer
BBBryan Buchholz
Bryan Buchholz
DDDenise R. Dunlap
Denise R. Dunlap
DMDavid D. McManus
David D. McManus
The National Institutes of Health (NIH) launched the Rapid Acceleration of Diagnostics (RADx SM ) Tech initiative to support the development and commercialization of novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) point-of-care test devices. The primary objective of the Clinical Studies Core (CSC) was to perform SARS-CoV-2 device studies involving diverse populations and settings. Within a few months, the infrastructure for clinical studies was developed, including a master protocol, digital study platform, data management system, single IRB, and multi-site partnerships. Data from some studies are being used to support Emergency Use Authorization of novel SARS-CoV-2 test devices. The CSC reduced the typical time and cost of developing medical devices and highlighted the impactful role of academic and NIH partnership in addressing public health needs at a rapid pace during a global pandemic. The structure, deployment, and lessons learned from this experience are widely applicable to future in vitro diagnostic device clinical studies.

24 November 2020 in Frontiers in Immunology
Verified
Journal Article
Open access
PDF file
EMEmma C. Materne
Emma C. Materne
DLDaniele Lilleri
Daniele Lilleri
FGFrancesca Garofoli
Francesca Garofoli
GLGiuseppina Lombardi
Giuseppina Lombardi
MFMilena Furione
Milena Furione
LGLaura L. Gibson
Laura L. Gibson
Background: Congenital cytomegalovirus (cCMV) infection is the most common infection acquired before birth and from which about 20% of infants develop permanent neurodevelopmental effects regardless of presence or absence of symptoms at birth. Viral escape from host immune control may be a mechanism of CMV transmission and infant disease severity. We sought to identify and compare CMV epitopes recognized by mother-infant pairs. We also hypothesized that if immune escape were occurring, then one pattern of longitudinal CD8 T cell responses restricted by shared HLA alleles would be maternal loss (by viral escape) and infant gain (by viral reversion to wildtype) of CMV epitope recognition.Methods: The study population consisted of 6 women with primary CMV infection during pregnancy and their infants with cCMV infection. CMV UL83 and UL123 peptides with known or predicted restriction by maternal MHC class I alleles were identified, and a subset was selected for testing based on several criteria. Maternal or infant cells were stimulated with CMV peptides in the IFN-γ ELISpot assay.Results: Overall, 14 of 25 (56%; 8 UL83 and 6 UL123) peptides recognized by mother-infant pairs were not previously reported as CD8 T cell epitopes. Of three pairs with longitudinal samples, one showed maternal loss and infant gain of responses to a CMV epitope restricted by a shared HLA allele.Conclusions: CD8 T cell responses to multiple novel CMV epitopes were identified, particularly in infants. Moreover, the hypothesized pattern of CMV immune escape was observed in one mother-infant pair. These findings emphasize that knowledge of paired CMV epitope recognition allows exploration of viral immune escape that may operate within the maternal-fetal system. Our work provides rationale for future studies of this potential mechanism of CMV transmission during pregnancy or clinical outcomes of infants with cCMV infection.

Verified
Journal Article
Open access
PDF file
CGCheryl Glovsky
Cheryl Glovsky
KCKendall Carroll
Kendall Carroll
NCNaomi Clark
Naomi Clark
PCPeter Colleran
Peter Colleran
VCVanessa Colleran
Vanessa Colleran
MCMichael Saul Cohen
Michael Saul Cohen
This study sought to assess the current state of screening for congenital cytomegalovirus infection in newborns among birth hospitals and newborn nurseries in the state of Massachusetts. A survey assessing hospital protocols for cytomegalovirus testing in newborns was distributed to all birth hospitals and newborn nurseries in Massachusetts from November 2020 to February 2021. 73.3% of hospitals responded to at least one survey question. Of these, fewer than half (48.5%) had any established approach for neonatal cytomegalovirus screening. Salivary polymerase chain reaction was the most common testing modality. Most hospitals did not perform confirmatory testing for positive test results. Most respondents (87.9%) did not know or did not answer how results of cCMV screening were reported to families and who was responsible for coordinating care for cCMV-infected infants. We conclude that congenital cytomegalovirus screening protocols are absent or incomplete in most Massachusetts birth hospitals and newborn nurseries. A cohesive strategy involving standardized education and screening guidelines is needed to reduce the incidence and burden of congenital cytomegalovirus disease on children and their families.